CardioGenics Holdings Inc. (CGNH)

[rambler]

Watch for next week. Something huge finally we are hearing IMO.

[pontiyak]

Thats a long trend.... hope it breaks out soon..

[SPM555]

CGNH Chart, watching for this trendline resistance to be broken.

http://onlycharts.com

[webmoney]

Just when I think I have seen it all. We have this!

http://www.sec.gov/Archives/edgar/data/1089029/000114420411012362/v213342_8k.htm

[webmoney]

Not very promising as you can see!

http://freerealtime.brand.edgar-online.com/DisplayFiling.aspx?TabIndex=2&FilingID=7684241&companyid=65826&ppu=%252fdefault.aspx%253fsym%253dcgnh%2526amp%253b

[rambler]

By the way, 3 is one of the luckiest numbers next to 8 in Chinese numerology. Coincidence? Maybe?

[rambler]

Sorry accidentally showed up 3 times. Not meant to.

[rambler]

Pulled this of another board but very true indeed.

Most of you have already seen what I am posting here in the provided links but for those who have not they should click on the links to fully understand the significance and huge potential of this company and why. Here I post all the information on Cardiogenics Holdings Inc with links to the video interview and the link for the medical publication and another "VERY" interesting headline. When you examine it very closely I am sure you will understand that there are a number of potential outcomes for this company and without a doubt one if not more of those outcomes is an absolute. You have to ask yourself in a corporate analytical way is it very possible we could see a takeover or buyout which will obviously see tremendous financial gains for everyone, shareholders and company? The fundamentals of this company will soon show why major pharmaceuticals are interested in a very serious way in this company's technology.

With your own research into this company I believe you will have no doubt about the eventual outcome for this company. Our own research has already concluded that without a doubt this company's technology is about to revolutionize the entire medical profession and industry globally and its market is in the billions. It has already been tested and re-tested by both the company and Merck and is also being tested against medical lab equipment in hospitals and has, as far as we can deduce from our sources, already outperformed with more accuracy and speed such lab equipment costing a quarter of a million dollars and more. The commercialization process is to begin for the bead portion of the market with Merck and "potentially" maybe other major corporations eyeing it with serious intent. The world market is in the billions, so it would be the wisest move for other major corporations to increase their revenue stream and their corporate growth, therefore this assumption has to be obvious. The final outcome no matter which route, means tremendous financial gains for the company and its shareholders.

On fundamentals alone the company has enormous financial potential for the investing public and the company, and coincidentally there is also a tremendous short position ( naked of between 30 to 50 million ) which will further boost the value for the investment community, but on fundamentals alone it will speak for itself. It must also be emphasized here that this technology is also for 205 other diseases, cancer, diabetes, Aids, etc, etc, not just cardiac markers and that is all that is being quantified in market value at the moment. So just imagine the full value of this technolgogy then?

With an annual growth of 5%, the world market for cardiac markers is expected to reach $1.05 billion by 2012.2
The market for professional POC immunoassays is estimated at $1.625 billion; with 14% growth, this market segment will reach $2.77 billion in 2012.2

View the following links and you will better understand the significance of this technology:

video interview:
To watch the segment online, please visit:
http://watch.bnn.ca/after-hours/august-2010/after-hours-august-16-2010/ - clip337168
The segment is also posted to the following links:
YouTube -

Company Website - http://www.cardiogenics.com/video.html

The article in the medical publication can be accessed online at:
http://www.mddionline.com/article/improving-diagnosis-times-new-point-care-technology

For interest sake I provide the following also which is a very strong possibility given the value of this technology worldwide.

CGNH CHAIRMAN SOLD HIS COMPANY FOR $ 1.75 BILLION TO WPI

. Neil Tabatznik

Acting Chairman of the Board
Cardiogenics Holdings Inc
Mississauga , ON
Sector: HEALTHCARE / Diagnostic Substances

59 Years Old
Mr. Tabatznik is the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in 2000, and has seen rapid growth from $0 to $700 million in 8 years. The Arrow Group has sales operations in 5 continents and employs more than 1000 people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. (1993-2000), which was acquired by MerckKGaA in 1994 and is now a part of Mylan Inc. the world's third largest generic and specialty pharmaceutical company. He was a Barrister-at-Law in London and was called to the Bar of England and Wales in 1978. He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.


Watson to Acquire Arrow Group
-- Arrow Will Expand Watson's Global Commercial Footprint -- Transaction Expected to be Accretive to Cash Earnings Per Share in 2010 Before Synergies -- Enhances Watson's Long Term Growth Profile
MORRISTOWN, N.J., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in a global pharmaceutical company with over $3 billion in revenue, commercial operations in over 20 countries, and a robust product portfolio and pipeline. Watson expects the transaction to close in the second half of 2009, and be accretive to cash earnings per share in 2010 before synergies.
Arrow is one of the fastest growing generic pharmaceutical companies in the world, generating $647 million in revenues in 2008, representing a 67% organic compound annual growth rate since 2001. Arrow markets more than 100 molecules in over 20 different countries, including key markets such as Canada, France and the U.K. In addition, Arrow has an extensive pipeline that will be launched across multiple markets, including significant potential U.S. launches in each of the next three years. Arrow has approximately 1,000 employees worldwide, including more than 250 in R&D.

[rambler]

Pulled this of another board but very true indeed.

Most of you have already seen what I am posting here in the provided links but for those who have not they should click on the links to fully understand the significance and huge potential of this company and why. Here I post all the information on Cardiogenics Holdings Inc with links to the video interview and the link for the medical publication and another "VERY" interesting headline. When you examine it very closely I am sure you will understand that there are a number of potential outcomes for this company and without a doubt one if not more of those outcomes is an absolute. You have to ask yourself in a corporate analytical way is it very possible we could see a takeover or buyout which will obviously see tremendous financial gains for everyone, shareholders and company? The fundamentals of this company will soon show why major pharmaceuticals are interested in a very serious way in this company's technology.

With your own research into this company I believe you will have no doubt about the eventual outcome for this company. Our own research has already concluded that without a doubt this company's technology is about to revolutionize the entire medical profession and industry globally and its market is in the billions. It has already been tested and re-tested by both the company and Merck and is also being tested against medical lab equipment in hospitals and has, as far as we can deduce from our sources, already outperformed with more accuracy and speed such lab equipment costing a quarter of a million dollars and more. The commercialization process is to begin for the bead portion of the market with Merck and "potentially" maybe other major corporations eyeing it with serious intent. The world market is in the billions, so it would be the wisest move for other major corporations to increase their revenue stream and their corporate growth, therefore this assumption has to be obvious. The final outcome no matter which route, means tremendous financial gains for the company and its shareholders.

On fundamentals alone the company has enormous financial potential for the investing public and the company, and coincidentally there is also a tremendous short position ( naked of between 30 to 50 million ) which will further boost the value for the investment community, but on fundamentals alone it will speak for itself. It must also be emphasized here that this technology is also for 205 other diseases, cancer, diabetes, Aids, etc, etc, not just cardiac markers and that is all that is being quantified in market value at the moment. So just imagine the full value of this technolgogy then?

With an annual growth of 5%, the world market for cardiac markers is expected to reach $1.05 billion by 2012.2
The market for professional POC immunoassays is estimated at $1.625 billion; with 14% growth, this market segment will reach $2.77 billion in 2012.2

View the following links and you will better understand the significance of this technology:

video interview:
To watch the segment online, please visit:
http://watch.bnn.ca/after-hours/august-2010/after-hours-august-16-2010/ - clip337168
The segment is also posted to the following links:
YouTube -

Company Website - http://www.cardiogenics.com/video.html

The article in the medical publication can be accessed online at:
http://www.mddionline.com/article/improving-diagnosis-times-new-point-care-technology

For interest sake I provide the following also which is a very strong possibility given the value of this technology worldwide.

CGNH CHAIRMAN SOLD HIS COMPANY FOR $ 1.75 BILLION TO WPI

. Neil Tabatznik

Acting Chairman of the Board
Cardiogenics Holdings Inc
Mississauga , ON
Sector: HEALTHCARE / Diagnostic Substances

59 Years Old
Mr. Tabatznik is the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in 2000, and has seen rapid growth from $0 to $700 million in 8 years. The Arrow Group has sales operations in 5 continents and employs more than 1000 people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. (1993-2000), which was acquired by MerckKGaA in 1994 and is now a part of Mylan Inc. the world's third largest generic and specialty pharmaceutical company. He was a Barrister-at-Law in London and was called to the Bar of England and Wales in 1978. He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.


Watson to Acquire Arrow Group
-- Arrow Will Expand Watson's Global Commercial Footprint -- Transaction Expected to be Accretive to Cash Earnings Per Share in 2010 Before Synergies -- Enhances Watson's Long Term Growth Profile
MORRISTOWN, N.J., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in a global pharmaceutical company with over $3 billion in revenue, commercial operations in over 20 countries, and a robust product portfolio and pipeline. Watson expects the transaction to close in the second half of 2009, and be accretive to cash earnings per share in 2010 before synergies.
Arrow is one of the fastest growing generic pharmaceutical companies in the world, generating $647 million in revenues in 2008, representing a 67% organic compound annual growth rate since 2001. Arrow markets more than 100 molecules in over 20 different countries, including key markets such as Canada, France and the U.K. In addition, Arrow has an extensive pipeline that will be launched across multiple markets, including significant potential U.S. launches in each of the next three years. Arrow has approximately 1,000 employees worldwide, including more than 250 in R&D.

[rambler]

[color=red]Pulled this of another board but very true indeed.

Most of you have already seen what I am posting here in the provided links but for those who have not they should click on the links to fully understand the significance and huge potential of this company and why. Here I post all the information on Cardiogenics Holdings Inc with links to the video interview and the link for the medical publication and another "VERY" interesting headline. When you examine it very closely I am sure you will understand that there are a number of potential outcomes for this company and without a doubt one if not more of those outcomes is an absolute. You have to ask yourself in a corporate analytical way is it very possible we could see a takeover or buyout which will obviously see tremendous financial gains for everyone, shareholders and company? The fundamentals of this company will soon show why major pharmaceuticals are interested in a very serious way in this company's technology.

With your own research into this company I believe you will have no doubt about the eventual outcome for this company. Our own research has already concluded that without a doubt this company's technology is about to revolutionize the entire medical profession and industry globally and its market is in the billions. It has already been tested and re-tested by both the company and Merck and is also being tested against medical lab equipment in hospitals and has, as far as we can deduce from our sources, already outperformed with more accuracy and speed such lab equipment costing a quarter of a million dollars and more. The commercialization process is to begin for the bead portion of the market with Merck and "potentially" maybe other major corporations eyeing it with serious intent. The world market is in the billions, so it would be the wisest move for other major corporations to increase their revenue stream and their corporate growth, therefore this assumption has to be obvious. The final outcome no matter which route, means tremendous financial gains for the company and its shareholders.

On fundamentals alone the company has enormous financial potential for the investing public and the company, and coincidentally there is also a tremendous short position ( naked of between 30 to 50 million ) which will further boost the value for the investment community, but on fundamentals alone it will speak for itself. It must also be emphasized here that this technology is also for 205 other diseases, cancer, diabetes, Aids, etc, etc, not just cardiac markers and that is all that is being quantified in market value at the moment. So just imagine the full value of this technolgogy then?

With an annual growth of 5%, the world market for cardiac markers is expected to reach $1.05 billion by 2012.2
The market for professional POC immunoassays is estimated at $1.625 billion; with 14% growth, this market segment will reach $2.77 billion in 2012.2

View the following links and you will better understand the significance of this technology:

video interview:
To watch the segment online, please visit:
http://watch.bnn.ca/after-hours/august-2010/after-hours-august-16-2010/ - clip337168
The segment is also posted to the following links:
YouTube -

Company Website - http://www.cardiogenics.com/video.html

The article in the medical publication can be accessed online at:
http://www.mddionline.com/article/improving-diagnosis-times-new-point-care-technology

For interest sake I provide the following also which is a very strong possibility given the value of this technology worldwide.

CGNH CHAIRMAN SOLD HIS COMPANY FOR $ 1.75 BILLION TO WPI [color=red][/color]

. Neil Tabatznik

Acting Chairman of the Board
Cardiogenics Holdings Inc
Mississauga , ON
Sector: HEALTHCARE / Diagnostic Substances

59 Years Old
Mr. Tabatznik is the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in 2000, and has seen rapid growth from $0 to $700 million in 8 years. The Arrow Group has sales operations in 5 continents and employs more than 1000 people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. (1993-2000), which was acquired by MerckKGaA in 1994 and is now a part of Mylan Inc. the world's third largest generic and specialty pharmaceutical company. He was a Barrister-at-Law in London and was called to the Bar of England and Wales in 1978. He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.


Watson to Acquire Arrow Group
-- Arrow Will Expand Watson's Global Commercial Footprint -- Transaction Expected to be Accretive to Cash Earnings Per Share in 2010 Before Synergies -- Enhances Watson's Long Term Growth Profile
MORRISTOWN, N.J., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in a global pharmaceutical company with over $3 billion in revenue, commercial operations in over 20 countries, and a robust product portfolio and pipeline. Watson expects the transaction to close in the second half of 2009, and be accretive to cash earnings per share in 2010 before synergies.
Arrow is one of the fastest growing generic pharmaceutical companies in the world, generating $647 million in revenues in 2008, representing a 67% organic compound annual growth rate since 2001. Arrow markets more than 100 molecules in over 20 different countries, including key markets such as Canada, France and the U.K. In addition, Arrow has an extensive pipeline that will be launched across multiple markets, including significant potential U.S. launches in each of the next three years. Arrow has approximately 1,000 employees worldwide, including more than 250 in R&D.
[/color]

[pontiyak]

what I like and take comfort in, is that the share were sold to 13 different individuals. That rules out any sneaky tricks by a VC or HedgeHog©.

very nice.... and such a small amount appears to be going a long way. Thats good too.

Yak :)

[SJSTOCKSHARK]

Very good news! The company with little dilution now has enough funds to complete the FDA approval process for their POC Analyzer.

Also the PIPE shares are tied up for 6 months per rule 144 so there is no immediate ability to sell the restricted stock for a profit. Hopefully, in 6 months this company will have money coming in from bead sales and a license agreement for the POC analyzer, so we'll be in the home stretch.

[lawrenzo]

from the 8k filed today...

On November 3, 2010, CardioGenics Holdings Inc. (the “Company”) sold 3,861,150 shares of its common stock (the “ Private Placement Shares ”) to 13 investors (the “Investor(s)”) in exchange for $1,930,575, or $0.50 per share, pursuant to subscription agreements entered into between the Company and each Investor (the “ Subscription Agreements ”). The Private Placement Shares do not have any registration rights and are subject to the rights and restrictions of Rule 144. Further, no warrants were issued in connection with the private placement. All of the securities issuances referenced above were exempt from registration under Section 4 (2) of the Securities Act of 1933, as issuances not involving a public offering.

[rambler]

Fundamentals precisely, but the fundamentals you have not seen yet, but you can very easily analyze, are what will take this into a new realm. BB stock for now but it could soon become a member of the "Elite" in every respect. The market for its technology is in the billions and the technology will make all the other technology now in use obsolete, hence the wording it will "revolutionize the medical industry". Can you imagine what the major pharmaceuticals must be thinking right now?

[rambler]

No, I am not Midnight.

[SJSTOCKSHARK]

Your posts are by design obscure but interesting.

Certainly there is something you know or believe which gives you great confidence but most of us are still "in the dark." Is your first name "Midnight?"

Seriously, my excitement about this stock is based solely on the fundamentals. I can not remember a BB stock with this kind of potential. I bought a nice position but thought I had more time to build an even bigger position. Still I am very satisifed with my returns.

Good luck to all of us in this stock.

[SJSTOCKSHARK]

The shorting is still occurring:

20101103|CGNH|28551|52579|O

http://regsho.finra.org/FORFshvol20101103.txt

[rambler]

I just read your post 5886 on RB and you are right on in your thinking but it is even bigger and faster than you think. If you only knew what? and same with the rest of the posters, you would be loading up like there is no tomorrow. Very quickly this is absolutely not something to trade because of what is about to happen and just how high it will go will be mind boggling to say the least.

[rambler]

Just an addendum to what I just replied to you. This stock doesn't even need to be pumped when you understand the final outcome. There would be a major short squeeze and there would be no way of avoiding it for any of the shorts and for very good reason.

[rambler]

This is not pumping but if you had any idea what is about to happen with this company you would understand the price it is at right now is only the beginning of even bigger things.

[pontiyak]

Hi SJSTOCK :)...I worked all day (as I always do). I havn't heard or seen anything. I like the direction :).

Wish I could average down.... heavy sigh .

yak

[rambler]

You bet something is up!!! We are on the verge of very major things. We understand some funds have already begun looking very seriously for very good reason and some of that activity in a small way already was as a result and it is only the beginning. We could be expecting something at any time now and you already know that from what is taking place that this will completely revolutionize the medical industry and the major pharmaceuticals realize that very well.

[SJSTOCKSHARK]

Yak up .20 today. Is something up?

[SJSTOCKSHARK]

The IHub administrators moved quickly. I thank them for their timely response. We are now classified as a medical device company. Perhaps we will finally shed any association with JAGH as a company, at least on this Board. We do still appreciate their former shareholders who remain invested in Cardiogenics.

[pontiyak]

SJSTOCK..I hope for all you that which you speak of. I can't afford to average down, and the R/S has left me far from the beach.

I like what I see, but am constrained to cheer from from the cheap seats

yak

[SJSTOCKSHARK]

I see that Cardiogenics is still being categorized as a media company. I wrote the administrator and asked for a change in classification to a medical device company. I suggest like minded posters also write in and ask for the change. It will help others locate this stock board.

[SJSTOCKSHARK]

I look forward to seeing the results of the Merck distribution of the beads. For Merck to pay a royality to CGNH for these improved beads, speaks volumes about the product since they already had a substantial share of the market. I suspect Merck believes these better beads will allow them to dramatically increase their market share. The adoption of beads by Merck's customers alone would result in a good return for the early investors in this company.

If the CGNH beads become the standard in a billion dollar a year market, look out! If Merck takes a 50% market share or 500 million, this results in 150 million in revenue to CGNH with only a small increase in expenses. If The result is even $2.50 a share in profit applying a modest p/e ratio for a growth company like CGNH of 20 brings us to $50 a share.

That brings us to the POC analyzer where FDA approval alone would cause a rapid appreciation of the stock price. This may happen as early as the spring.

While nothing is ever guaranteed when investing in a speculative stock like CGNH, I am willing to take the risk on this one.

[pontiyak]

we have a few good people on RB that own this stock. I for one have followed this since the early days of JAG Media.

More for the fight against NSS, and now for the future potential.

:)yak

[rambler]

Good for you. You are one of the intelligent ones that most likely has done their real due diligence. There is much more to come and you will be one of the lucky ones. This could truly be everyones' retirement fund.

[SJSTOCKSHARK]

rambler, A nice summary. Presently, there is only a small group following this stock. I agree that CGNH has explosive potential much like DNDN. I have established a position but will add on any dips.

[rambler]

We will encapsulate our opinion in short here. This is potentially every investors opportunity of being in on what normally we only hear about "after the fact" when the best and biggest investment opportunities have already climbed out of our reach. Major pharmaceuticals are not looking at this just because they have nothing better to do. We are sure they see this as a huge revenue source and the rest of the equation of what they may do we will leave to your sensible conclusions of what can happen. We will close with this posting by posting what the Acting Chairman of the Board of Cardiogenics has already accomplished and you will understand, but Cardiogenics is even more valuable.


J. Neil Tabatznik

Acting Chairman of the Board
Cardiogenics Holdings Inc
Mississauga , ON
Sector: HEALTHCARE / Diagnostic Substances

59 Years Old
Mr. Tabatznik is the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in 2000, and has seen rapid growth from $0 to $700 million in 8 years. The Arrow Group has sales operations in 5 continents and employs more than 1000 people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. (1993-2000), which was acquired by MerckKGaA in 1994 and is now a part of Mylan Inc. the world's third largest generic and specialty pharmaceutical company. He was a Barrister-at-Law in London and was called to the Bar of England and Wales in 1978. He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.

Watson to Acquire Arrow Group
-- Arrow Will Expand Watson's Global Commercial Footprint -- Transaction Expected to be Accretive to Cash Earnings Per Share in 2010 Before Synergies -- Enhances Watson's Long Term Growth Profile
MORRISTOWN, N.J., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in a global pharmaceutical company with over $3 billion in revenue, commercial operations in over 20 countries, and a robust product portfolio and pipeline. Watson expects the transaction to close in the second half of 2009, and be accretive to cash earnings per share in 2010 before synergies.
Arrow is one of the fastest growing generic pharmaceutical companies in the world, generating $647 million in revenues in 2008, representing a 67% organic compound annual growth rate since 2001. Arrow markets more than 100 molecules in over 20 different countries, including key markets such as Canada, France and the U.K. In addition, Arrow has an extensive pipeline that will be launched across multiple markets, including significant potential U.S. launches in each of the next three years. Arrow has approximately 1,000 employees worldwide, including more than 250 in R&D.

[rambler]

After viewing what we posted above you will understand that this is not only big, but for investors an extremely huge potential financial gain, and could become every investors retirement. It will save hundreds of millions of lives worldwide, and save the medical industry hundreds of millions of dollars because of the speed and accuracy of diagnosis which, without this technology has not been achieved even by the most expensive hospital or laboratory equipment costing more than a quarter of a million dollars versus this equipment which can be had in any doctors office, paramedic vehicle or any lab for that matter, and there is no competition in the world to rival this. The key is also in Cardiogenics silver coated paramagnetic beads ( patented ) which are 5 or more times effective than any of the beads now used by any competitor making the old beads obsolete. Every competitor now has no choice but to use Cardiogenics beads. The market from what you will have seen is in the billions worldwide. Do you now understand why major pharmaceuticals are eyeing this very closely???!!! From the information you will see that it is not only for cardiac markers, but also for 205 other diseases, cancer, Aids, etc, etc!!!

[rambler]

Also important click on link for medical publication putting Cardiogenics alongside the names of Roche, Siemens, Johnson&Johnson and Abbot and you will understand why the biggest pharmaceuticals in the world are looking very closely at this company!!!

CardioGenics Featured on Cover of Medical Device & Diagnostic Industry Magazine
Wed Oct 6, 9:00 AM
Email Story IM Story Printable View

MISSISSAUGA, Ontario, Oct. 6 /PRNewswire/ -- Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTC Bulletin Board: CGNH.OB), has authored a cover story for this month's Medical Device & Diagnostic Industry Magazine (MD+DI) which addresses improvements in diagnostic times using point-of-care technology. In the article, titled "Improving Diagnosis Times with New Point-of-Care Technology," Dr. Gawad reviews the in-vitro diagnostics market and the growth of point-of-care testing.

In addition to reviewing other point-of-care devices, Dr. Gawad describes the operation of the QL Care Analyzer(TM), CardioGenics' point-of-care immunoassay platform that will allow a heart attack diagnosis to be made in as little as 15 minutes vs. the national average of 2.8 hours required for test results from a central lab. CardioGenics expects to submit to the FDA a 510K application for the QL Care Analyzer(TM) (and its first cardiac test, Troponin-I) during Q1 2011 and to have both commercialized by Q2 2011.

The article can be accessed online at:

http://www.mddionline.com/article/im...are-technology

About Medical Device & Diagnostics Industry

Medical Device & Diagnostic Industry is a leading monthly magazine written exclusively for original equipment manufacturers of medical devices and in vitro diagnostic products. The goal of MD&DI is to help industry professionals develop, design, and manufacture medical products that comply with complex and demanding regulations and market requirements. MD&DI is published 12 times each year, along with two additional issues of its Guide to Outsourcing supplement.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care(TM) Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.

[rambler]

Click on the link for the Business News Network interview video which will show you why Cardiogenics is about to revolutionize the medical industry.

CardioGenics Featured on Canada's Business News Network
Wed Aug 18, 9:52 AM
Email Story IM Story Printable View

MISSISSAUGA, Ontario, Aug. 18 /PRNewswire-FirstCall/ -- Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTC Bulletin Board: CGNH.OB), developer of the ultra-sensitive QL Care(TM) Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, took part in an interview on Canada's Business News Network (BNN) on Monday, August 16th to discuss the market potential and technical advantages of the Company's paramagnetic beads and QL Care Analyzer(TM).

On the BNN program "After Hours," Andrew Bell visited Dr. Gawad at CardioGenics' office in Mississauga and spoke with him about how the Company's technology makes it possible to speed up diagnostic tests for heart attack and other conditions. Dr. Gawad explained how the Company's silver-coated paramagnetic beads represent a sizeable advantage in testing sensitivity and will allow CardioGenics to become a significant player in a market estimated at more than $1 billion. He also outlined the Company's distribution agreement of the beads with Merck, which will begin commercial shipments of the CardioGenics beads in September 2010. Additionally, Dr. Gawad described the operation of the QL Care Analyzer(TM), the Company's Point-Of-Care immunoassay platform that will allow a heart attack diagnosis to be made in as little as 15 minutes vs. the national average of 2.8 hours required for testing results from a central lab. Dr. Gawad expects to submit to the FDA a 510K application for the QL Care Analyzer(TM) (and its first cardiac test, Troponin-I) during Q1 2011 and to have both commercialized by Q2 2011.

"It was an honor to talk with Andrew on BNN," said Dr. Gawad. "Media attention like this is good for us as our business continues to grow. As I mentioned during the interview, CardioGenics' technology has the potential to save the lives of those who have experienced heart attacks and other conditions, while our distribution agreement with Merck augurs well for our future financial success."

After Hours is a show that gets you caught up on all the day's developments--and offers insight to get you primed for tomorrow. To watch the segment online, please visit:

http://watch.bnn.ca/after-hours/augu...ugust-16-2010/ - clip337168

The segment is also posted to the following links:

YouTube -

Company Website - http://www.cardiogenics.com/video.html

About Business News Network (BNN)

Business News Network (BNN) is Canada's only business and financial news network, and is currently available in about 4.5 million Canadian homes. Its editorial team features business journalists, entrepreneurs and financial professionals that deliver up-to-the-minute business news, commentary and interviews with leading business newsmakers.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care(TM) Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com

[SJSTOCKSHARK]

up another .13 today already.....unreal!

[pontiyak]

yes...it's nice to see :)

[SJSTOCKSHARK]

Up another 28% today to $1.06 and no buzz or news. WOW!

[SJSTOCKSHARK]

The stock price has held up well in light of the low volume and lack of news.

I am surprised at the lack of buzz about this stock after the Zacks report. Since Yak didn't post this article here, I will.

"CardioGenics Featured on Cover of Medical Device & Diagnostic Industry Magazine
Wed Oct 6, 9:00 AM


MISSISSAUGA, Ontario, Oct. 6 /PRNewswire/ -- Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTC Bulletin Board: CGNH.OB), has authored a cover story for this month's Medical Device & Diagnostic Industry Magazine (MD+DI) which addresses improvements in diagnostic times using point-of-care technology. In the article, titled "Improving Diagnosis Times with New Point-of-Care Technology," Dr. Gawad reviews the in-vitro diagnostics market and the growth of point-of-care testing.


In addition to reviewing other point-of-care devices, Dr. Gawad describes the operation of the QL Care Analyzer(TM), CardioGenics' point-of-care immunoassay platform that will allow a heart attack diagnosis to be made in as little as 15 minutes vs. the national average of 2.8 hours required for test results from a central lab. CardioGenics expects to submit to the FDA a 510K application for the QL Care Analyzer(TM) (and its first cardiac test, Troponin-I) during Q1 2011 and to have both commercialized by Q2 2011.


The article can be accessed online at:

http://www.mddionline.com/article/improving-diagnosis-times-new-point-care-technology


About Medical Device & Diagnostics Industry


Medical Device & Diagnostic Industry is a leading monthly magazine written exclusively for original equipment manufacturers of medical devices and in vitro diagnostic products. The goal of MD&DI is to help industry professionals develop, design, and manufacture medical products that comply with complex and demanding regulations and market requirements. MD&DI is published 12 times each year, along with two additional issues of its Guide to Outsourcing supplement.




This company's PR firms are doing an excellent job, so where is the buzz?

[SJSTOCKSHARK]

Zack's updates and restates their opinion:

http://cardiogenics.com/press_releases/Press_Release_09_23_10.pdf

[StormyStocks]

We are looking good overall. Upward bound!

[pontiyak]

most shareholders either don't know this board exists, or hate IHub.
They are here...

http://ragingbull.quote.com/mboard/boards.cgi?board=CGNH

yak

[StormyStocks]

Wild, no posters. Nadda happening here. This is unreal, I just don't get it. This stock is good. I know some are skeptical, but come on. I am here and lovin this!!!!

[StormyStocks]

I continue to be surprised at the lack of postings here as well. I am thinking they are perhaps a bit concerned about what happened with the R/S previously. Not to mention, with a float a low as this any buying will move the stock price up. Guess we will find out soon enough.

[rambler]

For a company that is an obvious takeover or buyout candidate this board is absolutely quiet. It should be loaded with posters. The smart ones are going to make the big money and everyone else will know about this one after the big move. You never get rich after the fact. It is always those intelligent enough to see the full green forest and not just the tree in front.

[rambler]

Amazingly no one even knows about this yet but when it begins to move up everyone will be wishing they had. There could even be a very good possibility of a complete takeover by one of the big ones IMO and probably not far off. That is my opinion but it only makes sense because of the value of the technology to the big ones. Absolutely undervalued but not for long.

[rambler]

This was on BNN (Canada's Business News Network yesterday. It talks about the technology and their deal with Merck and mentions this technology is over a billion dollars and they also have the analyzer that is also worth even more. Revenues are about to begin fast now and no competition out there for this technology and they have all the patents for all of it.

http://watch.bnn.ca/after-hours/august-2010/after-hours-august-16-2010/#clip337168

[rambler]

You should watch this video clip of Cardio's technology and you will understand where this stock will be headed very fast.

http://watch.bnn.ca/after-hours/august-2010/after-hours-august-16-2010/#clip337168

[rambler]

[pontiyak]

bored...CGNH, is just getting their feet underneath themselves.
Paramagnetic beads are just starting to be sold. The new machine should also help the bottom line, when it becomes avalible.
The R/S hurt many of us who supported the company.

Mixed feelings

yak

[boredhousewife]

Interesting stock tried to find it on Canadian Stock exchange but couldn't it only trades in US considering it is stationed here in Ontario. BNN has a clip today on what the company is doing and what they are doing. I do not own the stock as I haven't seen it trade yet as I am considering it. I do see it has done a stock split recently. The volume seems very low. I am actually surprised this stock is trading a bit low considering what it is doing with Merck and there maybe bio-tech companies that might be interested when they can approve their machine to test for heart attacks. I can also post for the posters what CNGH does and it's specs.JMHO

BNN Afterhours
5:30 PM Dr. Yahia Gawad
CEO
Cardiogenics
Focus: Heart attacks remain a leading cause of death and a big strain on the health care system. BNN sits down with Dr. Yahia Gawad, CEO, Cardiogenics a Canadian biotech looking to change that with a non-invasive heart attack test that would reduce wait times from over two hours to ten minutes.
Coming Up:
After Hours : August 16, 2010 : Advanced Heart Attack Diagnostics [08-16-10 5:20 PM]

One Canadian company is developing a technology to reduce the heart attack diagnostic process from an average of 2.8 hours to 15 minutes. BNN interviews Dr. Yahia Gawad, CEO, Cardiogenics.


Quote DetailsPrintable VersionShow MeOpen 0.42 P/E Ratio (TTM) --
Last Bid/Size 0.40 / 50 EPS (TTM) -0.83
Last Ask/Size 10.00 / 5 Next Earnings --
Previous Close 0.42 Beta 1.00
Volume 15,000 Last Dividend --
Average Volume 75,979 Dividend Yield 0.00%
Day High 0.42 Ex-Dividend Date --
Day Low 0.42 Shares Outstanding 24.6M
52 Week High 7.40 # of Floating Shares 49.61964M
52 Week Low 0.12 Short Interest as % of Float

52 Week Range Market Cap Sector/Industry
0.12 - 7.40 10.3M Technology/Scientific & Technical Instr.

Though CGNH has outperformed its Scientific & Technical Instr. peers over the last three months, over the past year it has lagged behind its peers.
Company DescriptionCardioGenics Holdings Inc., formerly JAG Media Holdings, Inc. is engaged in the development of products, targeting the immunoassay segment of the point-of-care (POC) in vitro diagnostic (IVD) testing market. The Company is focused on developing diagnostic test products to the IVD market. The Company's QL Care Analyzer (QLCA) is an automated point-of-care immunoassay analyzer. The QLCA uses a self-metering cartridge to perform immunoassay tests at the POC. Each cartridge is pre-loaded with the Company's beads, which have been coated with specific bind reagents and bioluminescent proteins linked to the target marker. A drop of whole blood added to the Cartridge creates the chemiluminescent reaction needed to deliver test results. It has developed four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. On July 31, 2009, it acquired CardioGenics Inc. (CardioGenics).


Growth

Investors need to know how much goods or services a company sells, and how much of that total it keeps as income (or profit) to grow its business or return to shareholders. In general, look for companies that sell and earn more than peers.

Net Profit Margin
293%
-137,131.00%-76,722%Insufficient data on CGNH for analysis of Net Profit Margin.

Earnings per Share Growth (TTM)
17,766%
-763.03%-961%EPS growth at CGNH is improving and is above the industry average. In addition there was no clear trend in EPS at CGNH over the last five years. The most recent EPS was -0.8327, a decrease of -763.03% over the previous year.


Sales Growth
8,313%
-2,200%Insufficient data on CGNH for analysis of Sales Growth.

Income Growth
2,717%
-2,038.03%-2,038%There was no clear trend in income growth at CGNH over the last five years.

Fundamentals

How is the company’s financial health?
When assessing the financial health of a company be aware that it is most relevant to compare the company against its peers as most ratios vary by industry. In addition, rarely will one ratio or statistic alone provide enough insight into the company to form and informed opinion.

Price/Earnings Ratio (TTM)
151.9x
0.2xInsufficient Price Earnings data on CGNH.

Price/Book (MRQ)
0.0x
14.8x1,087.0xLast quarter the Price to Book ratio at CGNH was 14.8x.


Return on Equity (TTM)
93%
-1,896%CGNH has a ROE of -114.99%

Total Debt/Total Capital (MRQ)
238%
0.00%0%CGNH uses little or no debt in its capital structure and may have less financial risk than the industry aggregate.

Provided by RBC